X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NOVARTIS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NOVARTIS TORRENT PHARMA/
NOVARTIS
 
P/E (TTM) x 28.6 391.6 7.3% View Chart
P/BV x 5.4 19.3 28.2% View Chart
Dividend Yield % 1.0 1.5 67.0%  

Financials

 TORRENT PHARMA   NOVARTIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
NOVARTIS
Mar-16
TORRENT PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,768982 180.0%   
Low Rs1,186556 213.2%   
Sales per share (Unadj.) Rs346.1252.9 136.8%  
Earnings per share (Unadj.) Rs55.262.1 88.8%  
Cash flow per share (Unadj.) Rs73.363.3 115.8%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %0.91.3 72.9%  
Book value per share (Unadj.) Rs257.1363.6 70.7%  
Shares outstanding (eoy) m169.2231.96 529.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.33.0 140.3%   
Avg P/E ratio x26.812.4 216.3%  
P/CF ratio (eoy) x20.112.2 165.8%  
Price / Book Value ratio x5.72.1 271.6%  
Dividend payout %25.416.1 157.7%   
Avg Mkt Cap Rs m249,88724,580 1,016.6%   
No. of employees `00011.80.8 1,566.6%   
Total wages/salary Rs m9,9341,801 551.5%   
Avg. sales/employee Rs Th4,971.510,748.9 46.3%   
Avg. wages/employee Rs Th843.22,395.2 35.2%   
Avg. net profit/employee Rs Th792.42,641.1 30.0%   
INCOME DATA
Net Sales Rs m58,5698,083 724.6%  
Other income Rs m2,233829 269.2%   
Total revenues Rs m60,8028,913 682.2%   
Gross profit Rs m13,773234 5,880.7%  
Depreciation Rs m3,06937 8,362.9%   
Interest Rs m2,0562 114,200.0%   
Profit before tax Rs m10,8811,025 1,061.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,545752 205.5%   
Profit after tax Rs m9,3361,986 470.1%  
Gross profit margin %23.52.9 811.6%  
Effective tax rate %14.273.4 19.4%   
Net profit margin %15.924.6 64.9%  
BALANCE SHEET DATA
Current assets Rs m53,84112,678 424.7%   
Current liabilities Rs m31,6122,433 1,299.3%   
Net working cap to sales %38.0126.7 29.9%  
Current ratio x1.75.2 32.7%  
Inventory Days Days9733 297.2%  
Debtors Days Days8422 372.5%  
Net fixed assets Rs m42,07969 60,808.2%   
Share capital Rs m846160 529.5%   
"Free" reserves Rs m42,65511,460 372.2%   
Net worth Rs m43,50111,621 374.3%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25014,400 703.1%  
Interest coverage x6.3570.5 1.1%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.6 103.0%   
Return on assets %11.313.8 81.5%  
Return on equity %21.517.1 125.6%  
Return on capital %19.623.6 83.3%  
Exports to sales %00.7 0.0%   
Imports to sales %018.6 0.0%   
Exports (fob) Rs mNA60 0.0%   
Imports (cif) Rs mNA1,503 0.0%   
Fx inflow Rs m20,066186 10,771.0%   
Fx outflow Rs m5,3041,821 291.3%   
Net fx Rs m14,762-1,635 -903.2%   
CASH FLOW
From Operations Rs m10,1272,531 400.1%  
From Investments Rs m-7,869-8,270 95.2%  
From Financial Activity Rs m-1,918-386 497.3%  
Net Cashflow Rs m212-6,125 -3.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 2.0 351.0%  
FIIs % 12.6 1.6 787.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.5 40.9%  
Shareholders   26,511 41,647 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; IT & Healthcare Stocks Gain(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.16% while the Hang Seng is down 0.49%. The Nikkei 225 is trading down by 0.43%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 17, 2018 10:37 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS